Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Japan
  4. Japan Exchange
  5. Kyowa Kirin Co., Ltd.
  6. Summary
    4151   JP3256000005

KYOWA KIRIN CO., LTD.

(4151)
  Report
 SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   End-of-day quote. End-of-day quote Japan Exchange
11/26/2021 11/29/2021 11/30/2021 12/01/2021 12/02/2021 Date
3340 3255 3170 3235 3265 Last
951000 850200 1701100 1164600 1130600 Volume
-2.48% -2.54% -2.61% +2.05% +0.93% Change
Estimated financial data (e)
Sales 2021 351 B 3 102 M 3 102 M
Net income 2021 50 020 M 442 M 442 M
Net cash position 2021 296 B 2 616 M 2 616 M
P/E ratio 2021 35,1x
Yield 2021 1,41%
Sales 2022 383 B 3 381 M 3 381 M
Net income 2022 61 211 M 541 M 541 M
Net cash position 2022 313 B 2 764 M 2 764 M
P/E ratio 2022 28,7x
Yield 2022 1,52%
Capitalization 1 754 B 15 532 M 15 503 M
EV / Sales 2021 4,15x
EV / Sales 2022 3,77x
Nbr of Employees 5 423
Free-Float 45,8%
More Financials
Company
Kyowa Kirin Co., Ltd., formerly Kyowa Hakko Kirin Co., Ltd. is a Japan-based company principally engaged in the manufacture and sale of medical drugs. The Company operates through two business segments. Pharmaceuticals segment conducts research, development, manufacture and sale of pharmaceuticals and other products. Bio-chemicals segment is involved in the research, development, manufacture and sale of... 
More about the company
Ratings of Kyowa Kirin Co., Ltd.
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about KYOWA KIRIN CO., LTD.
08:39aKyowa Kirin Declares its support for the recommendations of the Task Force on Climate-R..
AQ
11/30MEI Pharma Shares Rise 22% After Positive Data for Zandelisib Trial
DJ
11/30MEI Pharma Says Treatment With Follicular Lymphoma Drug Candidate Shows Complete Respon..
MT
11/30MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TI..
CI
11/12Kyowa Kirin Co., Ltd. Provides Update on Application for Marketing Authorisation of Ist..
CI
11/02Kyowa Kirin's Profit Slides 19% in Q3
MT
11/02Amgen Beats 3Q Expectations for Revenue, Adjusted EPS
DJ
11/02Amgen 3rd quarter profit beats, sales rise 4%
RE
11/02Nikkei 225 Down 0.4% on Stronger Yen Ahead of US Federal Reserve Meeting
MT
11/02Japanese stocks end lower ahead of Fed policy meeting
RE
11/01Japanese shares dip as investors brace for Fed taper timeline
RE
11/01XFOREST Therapeutics, Axcelead DDP and Kyowa Kirin Initiate an Collaboration in RNA Str..
CI
10/07Kyowa Kirin Co., Ltd. Announces Discontinuation for Developing KHK2375
CI
10/05Amgen's 'Underappreciated' Inflammation Portfolio Set to Trigger Growth, RBC Capital An..
MT
09/24KYOWA KIRIN : Long-Term CRYSVITA« ▼ (burosumab) Treatment Reduces the Burden of Dise..
BU
More news
News in other languages on KYOWA KIRIN CO., LTD.
11/02Le bénéfice de Kyowa Kirin chute de 19 % au troisième trimestre
11/02Le bénéfice d'Amgen au 3e trimestre est supérieur à celui de l'année précédente, les ve..
11/02Nikkei 225 en baisse de 0,4 % en raison du renforcement du yen avant la réunion de la R..
11/02MÄRKTE ASIEN/Tokio mit Gewinnmitnahmen - Notenbanken im Fokus
10/05Selon l'analyste de RBC Capital, le portefeuille de l'inflammation " sous-estimé " d'Am..
More news
Chart KYOWA KIRIN CO., LTD.
Duration : Period :
Kyowa Kirin Co., Ltd. Technical Analysis Chart | 4151 | JP3256000005 | MarketScreener
Technical analysis trends KYOWA KIRIN CO., LTD.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Last Close Price 3 265,00 JPY
Average target price 4 402,50 JPY
Spread / Average Target 34,8%
EPS Revisions
Managers and Directors
Masashi Miyamoto President, CEO & Representative Director
Motohiko Kawaguchi Executive Officer, Manager-Accounting & Finance
Nobuo Hanai Chairman
Mitsuo Satoh Executive Officer, GM-Research & Development
Kentaro Uryu Independent Outside Director
Sector and Competitors